Ascendis Pharma A/S Announces Full 12 months 2020 Economical Outcomes and Enterprise Update Convention Call on March 10

COPENHAGEN, Denmark, March 04, 2021 (World NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical business that makes use of its innovative TransCon™ systems to create product or service candidates that tackle unmet health care desires, these days declared that the enterprise will maintain a convention get in touch with and dwell webcast on Wednesday, March 10, 2021 at 4:30 p.m. Japanese Time (ET) to review its 2020 fiscal final results and give a business update.

Meeting Phone Specifics


Wednesday, March 10, 2021


4:30 p.m. ET/1:30 p.m. Pacific Time

Dial In (U.S.)


Dial In (International)


Entry Code


A dwell webcast of the convention phone will be out there on the Investors and Information area of the Ascendis Pharma web site at A webcast replay will be obtainable on this site soon following summary of the party for 30 times.

About Ascendis Pharma A/S

Ascendis Pharma is applying its progressive TransCon technologies to build a top, absolutely built-in biopharmaceutical firm focused on producing a meaningful big difference in patients’ lives. Guided by its main values of patients, science and enthusiasm, the firm utilizes its TransCon systems to build new and potentially very best-in-class therapies.

Ascendis Pharma currently has a pipeline of three unbiased endocrinology scarce ailment merchandise candidates and just one oncology solution candidate in clinical advancement. The corporation carries on to broaden into supplemental therapeutic locations to deal with unmet individual desires.

Ascendis is headquartered in Copenhagen, Denmark, with more workplaces in Heidelberg and Berlin, Germany, Palo Alto and Redwood Town, California, and Princeton, New Jersey.

Remember to stop by (for international details) or (for U.S. information and facts.)

Forward-Looking Statements

This press launch incorporates ahead-searching statements that involve considerable risks and uncertainties. All statements, other than statements of historical points, bundled in this press launch regarding Ascendis’ foreseeable future operations, ideas and goals of administration are ahead-searching statements. Examples of this kind of statements contain, but are not minimal to, statements relating to (i) Ascendis’ skill to implement its TransCon technologies to build a main, absolutely integrated biopharmaceutical firm, (ii) Ascendis’ products pipeline and growth into extra therapeutic places and (iii) Ascendis’ expectations about its potential to make the most of its TransCon technologies to create new and perhaps ideal-in-class therapies. Ascendis might not essentially reach the ideas, carry out the intentions or satisfy the anticipations or projections disclosed in the forward-seeking statements and you should really not area undue reliance on these forward-on the lookout statements. Genuine benefits or activities could vary materially from the plans, intentions, anticipations and projections disclosed in the ahead-searching statements. Many critical things could lead to true success or activities to vary materially from the ahead-wanting statements that Ascendis can make, which includes the pursuing: unexpected security or efficacy results in its oncology systems, TransCon hGH, TransCon PTH and TransCon CNP or other growth systems unexpected expenses connected to the advancement and opportunity commercialization of its oncology applications, TransCon hGH, TransCon PTH and TransCon CNP or other progress packages, advertising, common and administrative expenses, other investigate and advancement expenditures and Ascendis’ organization generally delays in the development of its oncology applications, TransCon hGH, TransCon PTH and TransCon CNP or other development courses connected to manufacturing, regulatory requirements, pace of affected person recruitment or other unforeseen delays dependence on 3rd get together brands to provide research drug for planned medical reports Ascendis’ ability to receive extra funding, if essential, to assistance its business enterprise things to do and the effects on its company from the around the world COVID-19 pandemic. For a additional description of the challenges and uncertainties that could cause actual benefits to vary from people expressed in these ahead-hunting statements, as well as risks relating to Ascendis’ enterprise in standard, see Ascendis’ prospectus nutritional supplement submitted on July 9, 2020 and Ascendis’ existing and future reviews submitted with, or submitted to, the U.S. Securities and Trade Fee (SEC), such as its Annual Report on Variety 20-F filed with the SEC on April 3, 2020. Forward-wanting statements do not mirror the opportunity impact of any long term in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may possibly enter into or make. Ascendis does not believe any obligation to update any ahead-seeking statements, besides as demanded by regulation.

Ascendis, Ascendis Pharma, the Ascendis Pharma emblem, the business brand and TransCon are emblems owned by the Ascendis Pharma Team. © March 2021 Ascendis Pharma A/S.